Curated News: National Cancer Institute (NCI)

Filters close
25-Aug-2023 11:05 AM EDT
Study could help explain why certain brain tumors don’t respond well to immunotherapy
University of California, Los Angeles (UCLA), Health Sciences

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds new light on why tumors that have spread to the brain from other parts of the body respond to immunotherapy while glioblastoma, an aggressive cancer that originates in the brain, does not.

Newswise: Enhancing Immune Defenses: Researchers Unveil the Secrets of Specialized T Cells to Conquer Tumors
28-Aug-2023 7:00 PM EDT
Enhancing Immune Defenses: Researchers Unveil the Secrets of Specialized T Cells to Conquer Tumors
University of California San Diego

Immunologists have uncovered new approaches to enhance protection from tumors and infections.

14-Aug-2023 7:05 PM EDT
Immunotherapy drug combo helps extend the lives of patients with metastatic melanoma
University of California, Los Angeles (UCLA), Health Sciences

A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors.

Released: 17-Aug-2023 10:00 AM EDT
Moffitt Awarded $5.5 Million to Study Virus-Associated Tumors Among Those Living with HIV in Sub-Saharan Africa
Moffitt Cancer Center

The Center for Immunization and Infection Research in Cancer at Moffitt Cancer Center is expanding its viral infection research in Africa. The cancer center has received a $5.5 million, five-year specialized research center grant (U54CA277834) from the National Cancer Institute to investigate virus-associated tumors that disproportionately impact men and women living with HIV in sub-Saharan Africa.

Released: 17-Aug-2023 8:45 AM EDT
Sylvester Comprehensive Cancer Center Tip Sheet - August 2023
Sylvester Comprehensive Cancer Center

New research shows blood cancers are often misdiagnosed, an NCI grant to develop a urine test for prostate cancer, a surgeon-scientist receives Sylvester’s first DoD grant to study pancreatic cancer, bolstering emergency preparedness for climate-driven disasters, and more are included in this month’s tip sheet .

Released: 17-Aug-2023 8:40 AM EDT
UC Irvine-led study links low-dose radiation to higher cancer risk
University of California, Irvine

Long-term exposure to low-dose radiation is linked to an increased risk of cancer, according to a study led by the University of California, Irvine. In the U.S., radiation exposure for the average person doubled between 1985 and 2006, mainly from medical imaging procedures such as CT scans, highlighting the need for its judicious use.

Released: 15-Aug-2023 11:35 AM EDT
Moffitt Researchers Use Mathematical Modeling and Dynamic Biomarkers to Characterize Metastatic Disease During Adaptive Therapy
Moffitt Cancer Center

In a new study published and included on the cover of the journal Cancer Research, Moffitt Cancer Center researchers demonstrate how mathematical modeling combined with dynamic biomarkers can be used to characterize metastatic disease and identify appropriate therapeutic approaches to improve patient outcomes.

Newswise: Sylvester Researcher Leads NCI Grant to Develop Urine Test to Lessen Need for Invasive Biopsies in Prostate Cancer Detection
Released: 15-Aug-2023 8:45 AM EDT
Sylvester Researcher Leads NCI Grant to Develop Urine Test to Lessen Need for Invasive Biopsies in Prostate Cancer Detection
Sylvester Comprehensive Cancer Center

A study to explore a new way to noninvasively detect prostate cancer is under way at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. The $2.5 million, five-year National Cancer Institute (NCI) grant is led by Sanoj Punnen, M.D.

Released: 14-Aug-2023 4:05 PM EDT
Scientists reveal how proteins drive growth of multiple cancer types
Washington University in St. Louis

Led by Washington University School of Medicine in St. Louis and other institutions around the world, the Clinical Proteomic Tumor Analysis Consortium has completed a deep analysis of the proteins driving cancer across multiple tumor types, information that can’t be assessed by genome sequencing alone. Understanding how proteins operate in cancer cells raises the prospect of new therapies.

Released: 14-Aug-2023 11:25 AM EDT
Study shows a new approach to target a deadly form of prostate cancer
Michigan Medicine - University of Michigan

A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.

Newswise: Sanford Burnham Prebys Cancer Center earns merit extension from NCI
Released: 9-Aug-2023 4:05 PM EDT
Sanford Burnham Prebys Cancer Center earns merit extension from NCI
Sanford Burnham Prebys

Sanford Burnham Prebys’ Cancer Center has received a rare and prestigious Merit Extension Award from the National Cancer Institute (NCI), recognizing and rewarding its earlier accomplishments as well as current research plans. The award extends the center’s current 5-year Cancer Center Support Grant (CCSG) for an additional two years.

Released: 7-Aug-2023 11:30 AM EDT
New Yale Study Shows Aerobic Exercise Relieves Pain for Ovarian Cancer Survivors
Yale Cancer Center/Smilow Cancer Hospital

One common side effect of treatment for ovarian cancer is chemotherapy-induced peripheral neuropathy (CIPN), which can damage peripheral nerves, causing severe pain and numbness. The effects can last for months – or even years — after completing chemotherapy. Currently, there is only one treatment with limited efficacy for CIPN.

Newswise: Researcher Leads NCI Grant to Develop Urine Test to Lessen Need for Invasive Biopsies in Prostate Cancer Detection
Released: 7-Aug-2023 11:10 AM EDT
Researcher Leads NCI Grant to Develop Urine Test to Lessen Need for Invasive Biopsies in Prostate Cancer Detection
University of Miami Health System, Miller School of Medicine

Sanoj Punnen, M.D., co-chair of the Genitourinary Site Disease Group at Sylvester Comprehensive Cancer Center and associate professor and vice chair of research, Desai Sethi Urology Institute, at the University of Miami Miller School of Medicine, is leading a $2.5 million, five-year National Cancer Institute (NCI) grant to explore a new way to noninvasively detect prostate cancer.

Newswise: New grant seeks to parse how the variegated nature of human breast cancer tumors helps cancer cells resist treatment
Released: 4-Aug-2023 8:00 AM EDT
New grant seeks to parse how the variegated nature of human breast cancer tumors helps cancer cells resist treatment
Sanford Burnham Prebys

The National Cancer Institute (NCI) has awarded a 5-year, $2.7 million grant to researchers at Sanford Burnham Prebys to investigate and elucidate the underlying cellular mechanisms that drive the most common form of breast cancer.

Newswise: Ovarian Cancer: New Biological Markers Found That May Predict Which Patients Won't Respond to Chemotherapy
31-Jul-2023 7:50 PM EDT
Ovarian Cancer: New Biological Markers Found That May Predict Which Patients Won't Respond to Chemotherapy
Mount Sinai Health System

Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy. The multicenter study, published online August 3 in Cell, reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC). The work also implicates possible therapeutic targets for these patients.

2-Aug-2023 6:05 PM EDT
Major Ovarian Cancer Discovery; Findings Published in Cell
University of Arkansas for Medical Sciences

The Birrer Laboratory at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute helped discover a proteogenomic signature in ovarian cancer that may improve the way the disease is treated around the world. The discovery, which identifies a 64-protein-gene signature that can predict primary treatment resistance in patients with high grade ovarian cancer, was published Aug. 3 in the journal Cell.

Newswise: Bladder Cancer: Cedars-Sinai Begins Project to Study Sex Differences
Released: 2-Aug-2023 10:45 AM EDT
Bladder Cancer: Cedars-Sinai Begins Project to Study Sex Differences
Cedars-Sinai

Cedars-Sinai Cancer investigators are spearheading a project, funded by a five-year, $11.2 million grant from the National Cancer Institute, part of the National Institutes of Health, to advance scientific knowledge of how biological differences between men and women affect bladder cancer.

Newswise: Children’s Hospital Los Angeles Researcher to Lead First-Ever International Liquid Biopsy Retinoblastoma Study
Released: 1-Aug-2023 6:05 AM EDT
Children’s Hospital Los Angeles Researcher to Lead First-Ever International Liquid Biopsy Retinoblastoma Study
Children's Hospital Los Angeles

The National Cancer Institute of the National Institutes of Health (NIH) has awarded Dr. Berry $2.8 million to lead the first prospective international retinoblastoma liquid biopsy study to date.

Newswise: Transcription Factors Contribute to Subtypes of Colorectal Cancers
Released: 27-Jul-2023 11:05 AM EDT
Transcription Factors Contribute to Subtypes of Colorectal Cancers
Johns Hopkins Medicine

New research in colorectal cancers directed by investigators at the Johns Hopkins Kimmel Cancer Center suggests that expression of transcription factors — proteins that help turn specific genes on or off by binding to nearby DNA — may play a central role in the degree of DNA methylation across the genome, contributing to the development of different subtypes of these cancers. Methylation is a process in which certain chemical groups attach to areas of DNA that guide genes’ on/off switches.

Newswise: New RNA-based Therapy Combats Melanoma in Mouse Models
24-Jul-2023 11:30 AM EDT
New RNA-based Therapy Combats Melanoma in Mouse Models
Mount Sinai Health System

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.



close
1.85555